OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	291
Author Correction: Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores	224
Assessing immunogenicity barriers of the HIV-1 envelope trimer	206
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	167
Reverse development of vaccines against antimicrobial-resistant pathogens	162
The dengue-specific immune response and antibody identification with machine learning	128
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	104
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	95
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	91
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	90
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	90
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	86
Mapping global public perspectives on mRNA vaccines and therapeutics	83
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	74
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	72
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	69
Protein engineering strategies for rational immunogen design	61
Rational development of a combined mRNA vaccine against COVID-19 and influenza	61
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	56
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	55
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	55
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	55
Antibody responses against influenza A decline with successive years of annual influenza vaccination	54
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	54
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis	54

Immune response against SARS-CoV-2 variants: the role of neutralization assays	54
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	54
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	53
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia	52
PfRH5 vaccine; from the bench to the vial	50
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	50
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	47
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	47
Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	46
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	43
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	42
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	42
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	42
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	41
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	41
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	41